Bing-Fei Xu

1.0k total citations · 1 hit paper
7 papers, 700 citations indexed

About

Bing-Fei Xu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Bing-Fei Xu has authored 7 papers receiving a total of 700 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Molecular Biology. Recurrent topics in Bing-Fei Xu's work include Cancer Immunotherapy and Biomarkers (2 papers), Adenosine and Purinergic Signaling (1 paper) and Cholesterol and Lipid Metabolism (1 paper). Bing-Fei Xu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (2 papers), Adenosine and Purinergic Signaling (1 paper) and Cholesterol and Lipid Metabolism (1 paper). Bing-Fei Xu collaborates with scholars based in China and Sweden. Bing-Fei Xu's co-authors include Hongxia Zhou, Yun Xia, Zhenyu Li, Gang Wu, Xiaofang Dai, Qi Han, Jipeng Guo, Pian Liu, Chen Zhang and Shi Lu and has published in prestigious journals such as Journal of Clinical Oncology, Molecular Cancer and European Journal of Cancer.

In The Last Decade

Bing-Fei Xu

7 papers receiving 699 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ferroptosis: A Novel Anti-tumor Action for Cisplatin

2017 606 citations Jipeng Guo, Bing-Fei Xu et al. Cancer Research and Treatment profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bing-Fei Xu China	6	513	453	399	131	39	7	700
Emma Lachaier France	5	562 1.1×	447 1.0×	460 1.2×	126 1.0×	19 0.5×	6	685
Lavanya Kondiparthi United States	7	487 0.9×	508 1.1×	388 1.0×	65 0.5×	37 0.9×	8	745
Qiangan Jing China	8	308 0.6×	319 0.7×	241 0.6×	128 1.0×	44 1.1×	13	586
Hironari Nishizawa Japan	11	337 0.7×	445 1.0×	243 0.6×	84 0.6×	55 1.4×	20	672
Rebecca Deasy United States	2	523 1.0×	482 1.1×	414 1.0×	101 0.8×	65 1.7×	3	737
Ting Hong China	8	347 0.7×	424 0.9×	350 0.9×	115 0.9×	33 0.8×	14	650
Ji Hyeon You South Korea	7	427 0.8×	418 0.9×	336 0.8×	82 0.6×	22 0.6×	8	608
Lin Zhong China	9	221 0.4×	304 0.7×	220 0.6×	111 0.8×	43 1.1×	21	523
Misha Mao China	14	399 0.8×	511 1.1×	373 0.9×	111 0.8×	69 1.8×	21	768

Countries citing papers authored by Bing-Fei Xu

Since Specialization

Citations

This map shows the geographic impact of Bing-Fei Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bing-Fei Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bing-Fei Xu more than expected).

Fields of papers citing papers by Bing-Fei Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bing-Fei Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bing-Fei Xu. The network helps show where Bing-Fei Xu may publish in the future.

Co-authorship network of co-authors of Bing-Fei Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Bing-Fei Xu. A scholar is included among the top collaborators of Bing-Fei Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bing-Fei Xu. Bing-Fei Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Zheng, Mei-Mei, Hai‐Yan Tu, Jin‐Ji Yang, et al.. (2021). Clinical outcomes of non–small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. European Journal of Cancer. 150. 23–30. 19 indexed citations

2.

Xu, Chong‐Rui, Yue‐Li Sun, Yang-Si Li, et al.. (2020). Safety of nivolumab/pembrolizumab in hepatitis B surface antigen-positive non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology. 38(15_suppl). e21670–e21670. 1 indexed citations

3.

Zhang, Chen, Bing-Fei Xu, Shi Lu, Ying Zhao, & Pian Liu. (2017). HN1 contributes to migration, invasion, and tumorigenesis of breast cancer by enhancing MYC activity. Molecular Cancer. 16(1). 90–90. 42 indexed citations

4.

Zhang, Chen, Shao-Hua Xie, Bing-Fei Xu, Shi Lu, & Pian Liu. (2017). Digitalis Use and the Risk of Breast Cancer: A Systematic Review and Meta-Analysis. Drug Safety. 40(4). 285–292. 6 indexed citations

5.

Guo, Jipeng, Bing-Fei Xu, Qi Han, et al.. (2017). Ferroptosis: A Novel Anti-tumor Action for Cisplatin. Cancer Research and Treatment. 50(2). 445–460. 606 indexed citations breakdown →

6.

Zhang, Chen, Bing-Fei Xu, & Pian Liu. (2016). Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer. Tumor Biology. 37(11). 14831–14839. 6 indexed citations

7.

Xu, Bing-Fei, et al.. (2016). Celecoxib induces apoptosis but up-regulates VEGF via endoplasmic reticulum stress in human colorectal cancer in vitro and in vivo. Cancer Chemotherapy and Pharmacology. 77(4). 797–806. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact